24 November 2015 - Novartis announced today that the European Commission has approved Entresto (sacubitril/valsartan) for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction.

For more details, go to: https://www.novartis.com/news/media-releases/novartis-heart-failure-medicine-entrestotm-receives-eu-approval